By John Vandermosten, CFANASDAQ:DYAI Dyadic International Inc. (NASDAQ:DYAI) has continued to maintain its high level of operational intensity since reporting first quarter earnings in early May. The company has been busy attending investor conferences, closing the trading day at NASDAQ on June 17th, advancing Ms. Rawson to CFO, joining...
By Brian Marckx, CFANASDAQ:AEMDREAD THE FULL AEMD RESEARCH REPORTFiscal Q4 2019 Financials, Operational UpdateAethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal fourth quarter ending March 31, 2019 and provided a business update. Revenue of $80k was recorded in the quarter, representing the initial payment under AEMD’s ongoing...
By John Vandermosten, CFA American Gene Technologies (AGT) is a genetic medicines company developing a portfolio of therapies that employ the company’s proprietary lentiviral vector (LV) platform to focus on disease in areas of unmet medical need. AGT’s pipeline consists of therapies for three different indications. The most advanced is...
By John Vandermosten, CFAOTC:PRED Over the last couple weeks Predictive Technology Group (OTC:PRED) has achieved two milestones in its advance towards validating and commercializing its endometriosis diagnostic test. On June 19th the company announced a research collaboration with Thermo Fisher Scientific and on June 24th presented new genetic findings...
By Brian Marckx, CFANASDAQ:DRRX | NASDAQ:PCRXREAD THE FULL DRRX RESEARCH REPORTPOSIMIR CRL Response Made. Favorable Decision Would Likely Mean Significant Upside to Our ModelThis morning, Durect (NASDAQ:DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR...
By Brian Marckx, CFANASDAQ:APM | OTC:RHHBYREAD THE FULL APM RESEARCH REPORT Aptorum Group Limited (NASDAQ:APM) went public through an initial public offering which closed in December 2018 and raised $12.0M (gross) from the sale of 761k common shares. The shares were added to the Morgan Stanley Capital International (MSCI)...
By John Vandermosten, CFANYSE:ZOM 85 million American families own a pet, mostly split between 60 million dog owners and 47 million cat owners1. These animal companions need health care just like people do. The high level of ownership stimulates the $19 billion2 in estimated veterinary care spending and...
By Brian Marckx, CFANASDAQ:MYOSREAD THE FULL MYOS RESEARCH REPORT Yesterday, MYOS Rens Technology (NASDAQ:MYOS) announced topline results from a study conducted at the University of California, Berkeley which further supports the role of (their proprietary) Fortetropin in the promotion of muscle growth. This study focused specifically on older adults...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAFREAD THE FULL MDNA.TO RESEARCH REPORTBusiness UpdateOn June 18, 2019, Medicenna Therapeutics Corp. (TSX:MDNA) (OTC:MDNAF) announced the presentation of preliminary topline results from the company’s ongoing Phase 2b trial of MDNA55, an IL-4R targeted toxin, in patients with recurrent glioblastoma (rGBM). The trial is...
By John Vandermosten, CFANYSE:CVM In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (NYSE:CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. ...